Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;74(3):477-492.
doi: 10.1161/HYPERTENSIONAHA.119.13412. Epub 2019 Jul 29.

Noncoding RNAs in Hypertension

Amela Jusic  1 , Yvan Devaux  2 ; EU-CardioRNA COST Action (CA17129)
Affiliations
Review

Noncoding RNAs in Hypertension

Amela Jusic et al. Hypertension. 2019 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Literature search. A, Flow chart methodology used for data extraction (original articles). PubMed search was performed using the keywords “noncoding RNA AND hypertension.” B, Distribution of evaluated and included original articles according to type of hypertension. CVD indicates cardiovascular disease; EHT, essential hypertension; mRNA, messenger RNA; ncRNA, noncoding RNA; NHT, nocturnal hypertension; OA, original articles; PAHT, pulmonary arterial hypertension; PHT, pulmonary hypertension; SNPs, single nucleotide polymorphisms; and WCHT, white coat hypertension.
Figure 2.
Figure 2.
Venn diagram of the number of microRNAs (miRNAs) overlap between different types of hypertension. MiRNA-21↑ and miR-130a↑ are upregulated in all types of hypertension. MiRNA-126↓ and miR-145↑ are common for essential hypertension (EHT) and pulmonary arterial hypertension (PAHT), while miR-204↓, miR-424↓ and miR-503↓ are downregulated in PAHT and PHT. ↑, upregulated; ↓, downregulated.
See this image and copyright information in PMC

References

    1. Adler AJ, Prabhakaran D, Bovet P, Kazi DS, Mancia G, Mungal-Singh V, Poulter N. Reducing cardiovascular mortality through prevention and management of raised blood pressure: a World Heart Federation Roadmap. Glob Heart. 2015;10:111–122. doi: 10.1016/j.gheart.2015.04.006. - PubMed
    1. Sekar D, Shilpa BR, Das AJ. Relevance of microRNA 21 in different types of hypertension. Curr Hypertens Rep. 2017;19:57. doi: 10.1007/s11906-017-0752-z. - PubMed
    1. Carretero OA, Oparil S. Essential hypertension: part II: treatment. Circulation. 2000;101:446–453. doi: 10.1161/01.cir.101.4.446. - PubMed
    1. Humbert M, Montani D, Evgenov OV, Simonneau G. Definition and classification of pulmonary hypertension. Handb Exp Pharmacol. 2013;218:3–29. doi: 10.1007/978-3-642-38664-0_1. - PubMed
    1. Cao Y, Yang Y, Wang L, Li L, Zhang J, Gao X, Dai S, Zhang Y, Guo Q, Peng YG, Wang E. Analyses of long non-coding RNA and mRNA profiles in right ventricle myocardium of acute right heart failure in pulmonary arterial hypertension rats. Biomed Pharmacother. 2018;106:1108–1115. doi: 10.1016/j.biopha.2018.07.057. - PubMed

Publication types